Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 1;105(11):e259-e260.
doi: 10.1097/TP.0000000000003923.

Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept

Johan Noble  1   2 , Antoine Langello  1 , William Bouchut  1 , Julien Lupo  3 , Dorothee Lombardo  1 , Lionel Rostaing  1   2
Affiliations
Comment

Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept

Johan Noble et al. Transplantation. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no funding or conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Response to SARS-CoV-2 vaccination in Belatacept Kidney transplant recipients. A, Comparison of anti–severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA positive immune responses in kidney transplant recipients at month 3 after vaccination who were either on belatacept or on tacrolimus immunosuppressive regimen. B, Anti–SARS-CoV-2 mRNA antibody titers in kidney transplant recipients who received belatacept. The dot-plot shows all anti–SARS-CoV-2 mRNA titers at months 2 and 3 after vaccination. The red point shows the average; the red bar represents the interquartile. C, anti–SARS-CoV-2 mRNA positive immune responses in belatacept-treated kidney transplant recipients after the third vaccination.
See this image and copyright information in PMC

Comment on

References

    1. Bertrand D, Hamzaoui M, Lemée V, et al. . Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021;32:ASN.2021040480. - PMC - PubMed
    1. Chavarot N, Ouedrani A, Marion O, et al. . Poor Anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept. Transplantation. 2021;105:e94–e95. - PubMed
    1. Ou MT, Boyarsky BJ, Chiang TPY, et al. . Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept. Transplantation. 2021;105:2119–2123. - PMC - PubMed
    1. Bal A, Pozzetto B, Trabaud M-A, et al. ; COVID SER Study Group. Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity, and association with virus neutralization test. Clin Chem. 2021;67:742–752. - PMC - PubMed
    1. Harritshøj LH, Gybel-Brask M, Afzal S, et al. . Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J Clin Microbiol. 2021;59:e02596–e02520. - PMC - PubMed